Trademarkia Logo

Canada

C$
GALXC PLUS
REGISTERED

on 10 May 2023

Last Applicant/ Owned by

DICERNA PHARMACEUTICALS INC.

87 Cambridgepark DriveCambridge MA 02140

US

Serial Number

2141457 filed on 14th Jul 2021

Registration Number

TMA1179576 registered on 10th May 2023

Registration expiry Date

14th Jul 2031

GALXC PLUS

Trademark usage description

oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, Read More

Vienna Information


26 . 3 . 4

Several triangles, juxtaposed, joined or intersectingPlusieurs triangles, juxtaposés, accolés ou se coupant

26 . 3 . 24

Triangles with dark surfaces or parts of surfacesTriangles avec surface ou partie de la surface foncée

25 . 7 . 1

Surfaces or backgrounds covered with repeated geometrical figures or designsSurfaces ou fonds couverts de figures ou de motifs géométriques répétés

25 . 7 . 8

Surfaces or backgrounds covered with other repeated geometrical figures or designsSurfaces ou fonds couverts d'autres figures ou motifs géométriques répétés

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 4

Letters embellished or decorated with a drawing or composed of a collection of drawingsLettres enjolivées ou ornées d'un dessin ou composées par un assemblage de dessins

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

29 . 1 . 4

BlueBleu

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

Classification Information


Class [005]
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.


Classification kind code

11

Class [042]
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections.


Classification kind code

11

Mark Details


Serial Number

2141457

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 222
on 13th Feb 2023
Opposition Start Date Notice Sent
Submitted for opposition 26
on 17th Jan 2023
Approved
Submitted for opposition 27
on 17th Jan 2023
Approval Notice Sent
Submitted for opposition 22
on 11th Jan 2023
Search Recorded
Submitted for opposition 256
on 22nd Aug 2022
Notification of Possible Opposition Sent
Submitted for opposition 257
on 21st Oct 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 20th Oct 2021
Formalized
Submitted for opposition 1
on 20th Oct 2021
Created
Submitted for opposition 228
on 14th Jul 2021
International Registration
Submitted for opposition 30
on 14th Jul 2021
Filed